To assess the efficacy of whole course management in patients with schizophrenia.

From January 2019 to Febuary 2020, one hundred and twenty-nine schizophrenia patients were recruited from Shihezi Oasis Hospital and divided into the study group (n=64) and control group (n=65) . Demographic data including gender, age, marital status and education level of all patients were recorded by researchers. Patients in the control group received the standard therapy. While, patients in the study group received the whole course management base on the standard therapy, and both of them were followed up for one year. Treatment efficacy in the two groups was assessed by Positive and Negative Syndrome Scale (PANSS, including positive, negative syndrome and the general psychopathological symptom score, used to assess the patient's psychiatric symptoms) , Social Functional Defect Screening Scale (SDSS, used to assess the degree of social functional defect) , and Activity of Daily Living Scale (ADL, used to assess the patient's ability of daily living) . And 8-item Morisky Medication Adherence Scale (MMAS-8, used to assess patient medication adherence) was used to assess medication compliance of discharged patients. And recurrence rates (used to evaluate clinical efficacy) were calculated in discharging patients only. All assessments were conducted before and 3, 6, 12 months after the study.

There were no significant differences between two groups in demographic factors including gender、age、marital status and education level and PANSS, ADL, SDSS, MMAS-8 scores (P>0.05) . Compared to the control group, there were lower scores of PANSS, SDSS and General Psychopathological Symptom Score at 6 and 12 month (P<0.05) . And in study group there also showed significantly lower scores of negative symptoms and ADL at 12 month (P<0.05) . Meanwhile, the post-intervention medication adherence was better in the study group (P<0.05) . However, there was no significant difference between the two groups about the recurrence rate (P>0.05) .

The whole course management could effectively alleviate the severity of schizophrenic, and could improve the ability to daily life, social functioning, as well as medication adherence in patients with schizophrenia.

探讨全病程管理模式在精神分裂症患者中的应用效果。

选取石河子绿洲医院2019年1月至2020年2月收治的129例精神分裂症患者为研究对象，采用随机数字表法分为对照组（n=64）和研究组（n=65），收集患者基本资料，包括性别、年龄、婚姻状况、文化程度等。对照组患者入组后给予常规诊疗模式干预，研究组患者入组后在常规诊疗模式干预基础上接受全病程管理模式干预，所有患者入组后持续观察12个月。于干预前及入组3、6、12个月时分别对两组患者进行疗效、日常生活能力、社会功能及用药依从性评估（仅限已出院患者），出院后评估复发率。疗效评估：以阳性与阴性症状量表（PANSS）总分（阳性症状量表评分+阴性症状量表评分+一般精神病理症状量表评分）评估患者精神症状、以日常生活能力量表（ADL）评分评估患者日常生活能力、以复发率（仅限已出院患者）评估临床疗效；以社会功能缺陷筛选量表（SDSS）评分评估患者社会功能缺陷程度；以用药依从性量表（MMAS-8）评分评估患者用药依从性。

干预前两组患者基本资料（性别、年龄、婚姻状况、文化程度等）及PANSS、ADL、SDSS、MMAS-8评分比较，差异均无统计学意义（P>0.05）。入组后研究组6、12个月的一般精神病理症状量表评分、PANSS总分、SDSS总分低于对照组（P<0.05）；入组12个月的阴性症状量表评分、ADL总分低于对照组（P<0.05）。研究组中入组且出院后持续观察3、6、12个月时的患者用药依从性优于对照组（P<0.05）。两组在入组且出院后持续观察12个月时患者的复发率比较，差异无统计学意义（P>0.05）。

全病程管理模式能有效减轻精神分裂症患者的精神症状，提高患者的日常生活能力、社会功能，同时提高其用药依从性。